Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.

Bryant A, Palma CA, Jayaswal V, Yang YW, Lutherborrow M, Ma DD.

Mol Cancer. 2012 Feb 20;11:8. doi: 10.1186/1476-4598-11-8.

2.

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50. doi: 10.1073/pnas.0800135105. Epub 2008 Feb 28.

3.

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.

Ovcharenko D, Stölzel F, Poitz D, Fierro F, Schaich M, Neubauer A, Kelnar K, Davison T, Müller-Tidow C, Thiede C, Bornhäuser M, Ehninger G, Brown D, Illmer T.

Exp Hematol. 2011 Oct;39(10):1030-1042.e7. doi: 10.1016/j.exphem.2011.07.008. Epub 2011 Jul 22.

PMID:
21784052
4.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.

Russ AC, Sander S, Lück SC, Lang KM, Bauer M, Rücker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L.

Haematologica. 2011 Dec;96(12):1783-91. doi: 10.3324/haematol.2011.046888. Epub 2011 Aug 31.

5.

MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.

Palma CA, Al Sheikha D, Lim TK, Bryant A, Vu TT, Jayaswal V, Ma DD.

Mol Cancer. 2014 Apr 5;13:79. doi: 10.1186/1476-4598-13-79.

6.

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.

Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R.

Blood. 2014 Apr 10;123(15):2412-5. doi: 10.1182/blood-2013-10-532374. Epub 2014 Mar 4.

7.

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status.

Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F.

J Hematol Oncol. 2012 Jun 8;5:26. doi: 10.1186/1756-8722-5-26.

8.

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.

Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, Kern W, Haferlach T.

Leukemia. 2011 Apr;25(4):615-21. doi: 10.1038/leu.2010.299. Epub 2011 Jan 14.

PMID:
21233837
9.

Differential expression of specific microRNA and their targets in acute myeloid leukemia.

Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L, Civiletto G, Messana F, Marfia A, Bica MG, Cascio L, Floridia PM, Mineo AM, Russo M, Fabbiano F, Santoro A.

Am J Hematol. 2010 May;85(5):331-9. doi: 10.1002/ajh.21667.

10.

Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia.

Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T, Andrew Lister T, Young BD, Debernardi S.

PLoS One. 2008 May 14;3(5):e2141. doi: 10.1371/journal.pone.0002141.

11.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD.

J Clin Oncol. 2008 Nov 1;26(31):5078-87. doi: 10.1200/JCO.2008.17.5554. Epub 2008 Sep 22. Erratum in: J Clin Oncol. 2008 Dec 20;26(36):6021.

12.

The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model.

Sportoletti P, Varasano E, Rossi R, Bereshchenko O, Cecchini D, Gionfriddo I, Bolli N, Tiacci E, Intermesoli T, Zanghì P, Masciulli A, Martelli MP, Falzetti F, Martelli MF, Falini B.

Blood. 2013 Apr 25;121(17):3447-58. doi: 10.1182/blood-2012-08-449553. Epub 2013 Feb 22.

13.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

14.

Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia.

Kim YK, Kim HN, Lee SR, Ahn JS, Yang DH, Lee JJ, Lee IK, Shin MG, Kim HJ.

Korean J Hematol. 2010 Mar;45(1):36-45. doi: 10.5045/kjh.2010.45.1.36. Epub 2010 Mar 31.

15.

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.

Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, Nicoletti I.

Leukemia. 2009 Oct;23(10):1731-43. doi: 10.1038/leu.2009.124. Epub 2009 Jun 11. Review.

PMID:
19516275
16.

Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.

Park BG, Chi HS, Park SJ, Min SK, Jang S, Park CJ, Kim DY, Lee JH, Lee JH, Lee KH.

Acta Haematol. 2012;127(2):63-71. doi: 10.1159/000331509. Epub 2011 Nov 18.

17.

[Screening and expression of CD34(+) cell-specific microRNA in acute myelogenous leukemia].

Wang GP, Zhang SQ, Zhu P, Peng MY, Tan SQ, Yin H, Xu YJ, Chen Y, Chen FP.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):541-5. Chinese.

PMID:
22967414
18.

MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B.

Blood. 2008 May 15;111(10):5078-85. doi: 10.1182/blood-2008-01-133355. Epub 2008 Mar 12.

19.

Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.

Du Pisani LA, Shires K.

Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):106-14. doi: 10.1016/j.hemonc.2015.06.009. Epub 2015 Jul 9.

20.

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, Ma H, Chen L, Venkannagari S, Ha K, Abhyankar S, Williams C, McGuirk J, Khoury HJ, Ustun C, Bhalla KN.

Blood. 2011 Sep 15;118(11):3096-106. doi: 10.1182/blood-2010-09-309674. Epub 2011 Jun 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk